Pharma

Industry hires and promotions: February 2017

Industry hires and promotions: February 2017

By

Novo Nordisk appoints new CEO, and more people moves for you to know about

On drug pricing, Acorda CEO is optimistic

On drug pricing, Acorda CEO is optimistic

By

Acorda CEO Ron Cohen applauded Marathon's move to pause the commercial activities for its new DMD drug.

Three kinds of drugs, like those that treat RA and diabetes, drive increase in spending

Three kinds of drugs, like those that treat RA and diabetes, drive increase in spending

By

Spending for inflammatory drugs like AbbVie's Humira and Amgen's Enbrel rose, while hepatitis C drugs showed decline.

Five things for pharma marketers to know: Tuesday, February 7, 2017

Five things for pharma marketers to know: Tuesday, February 7, 2017

By

Teva CEO steps down; Mylan to pay $96.5 million to settle pay-for-delay claims; Merck files Keytruda with the FDA for bladder cancer

Genentech Should Let Us See Its Herceptin Documentary

Genentech Should Let Us See Its Herceptin Documentary

By

The 2009 documentary offers a wealth of detail. Which is why it makes no sense that Genentech doesn't want you to see the damn thing.

10 ways healthcare companies are testing Instagram

10 ways healthcare companies are testing Instagram

By

Pharmaceutical and healthcare companies use a mix of corporate and brand accounts on Instagram, and some are turning to celebrity influencers.

How can drugmakers tell better stories? Try Instagram

How can drugmakers tell better stories? Try Instagram

By

The Kim Kardashian debacle aside, what makes the platform so potentially valuable to pharma and healthcare marketers is its visual story-telling capability.

WPP to merge Ogilvy CommonHealth, ghg, Sudler, and CMI into new company

WPP to merge Ogilvy CommonHealth, ghg, Sudler, and CMI into new company

By By

A WPP insider has been tapped as CEO of WPP Health & Wellness, and Ogilvy CommonHealth chairman/CEO Matt Giegerich is stepping down.

MM&M's top 5 stories in January 2017

MM&M's top 5 stories in January 2017

By

Merck and Aetna partner in value-based drug pricing; data scientists rising in the biopharma ranks; Japanese pharma leads digital health innovation

Pharma/Payer Collaboration: A Kumbaya Moment or a Passing Trend?

Pharma/Payer Collaboration: A Kumbaya Moment or a Passing Trend?

By

The idea is that each gets some of what it needs. Payers gain some control over cost, and pharma may get to stay on formulary.

Infographic: How Trump will affect healthcare marketing budgets

Infographic: How Trump will affect healthcare marketing budgets

A new survey found that 34% of healthcare and pharma marketers say that the election of President Trump will not affect their marketing budgets.

Five things for pharma marketers to know: Thursday, January 26, 2017

Five things for pharma marketers to know: Thursday, January 26, 2017

By

J&J to buy Actelion for $30 billion; Pfizer fights advertising ban related to Advil; almost half of women with breast cancer report severe side effects

Five things for pharma marketers to know: Wednesday, January 25, 2017

Five things for pharma marketers to know: Wednesday, January 25, 2017

By

Novartis forecasts slower growth in 2017; Actelion reports trial failure for PAH drug; HHS nominee Tom Price denies conflict of interest claims

Ryan Abbate, 2017 MAHF inductee, sets the record straight

Ryan Abbate, 2017 MAHF inductee, sets the record straight

By

The founder of Pacific Communications shares the details of his career as he is inducted into the Medical Advertising Hall of Fame.

Mike Lazur, 2017 MAHF inductee, on his medical advertising destiny

Mike Lazur, 2017 MAHF inductee, on his medical advertising destiny

By

He played a leading role during Torre Lazur's glory era as "the launch agency." Now he is being inducted into the Medical Advertising Hall of Fame.

Is Pharma Ready to Commit to the Startup World?

Is Pharma Ready to Commit to the Startup World?

Drugmakers have flirted with these pilots or partnerships, but few have fully embraced partnerships with digital health startups.

Healthcare communicators track Obamacare repeal debate

Healthcare communicators track Obamacare repeal debate

By

Many healthcare comms leaders are paying close attention to the debate between "access" to healthcare versus making it a requirement, experts say.

It's Time for the Healthcare Industry to Take Advantage of Programmatic

It's Time for the Healthcare Industry to Take Advantage of Programmatic

Still, pharmaceutical marketers must remember that maintaining regulatory compliance is all-important.

Five things for pharma marketers to know: Friday, January 20, 2017

Five things for pharma marketers to know: Friday, January 20, 2017

By

Pharma among top sponsors of Trump inauguration parties; AstraZeneca exec to replace GSK president of global pharmaceuticals; EpiPen rival to relaunch

Five things for pharma marketers to know: Wednesday, January 18, 2017

Five things for pharma marketers to know: Wednesday, January 18, 2017

By

Rep. Price to answer questions at confirmation hearing; 22 drugmakers invest in fighting disease in poor countries; FDA approves generic of Jazz's Xyrem

Industry hires and promotions: January 2017

Industry hires and promotions: January 2017

By

Endo hires new head of U.S. branded pharma, and three other people moves for you to know about.

Five things for pharma marketers to know: Thursday, January 12, 2017

Five things for pharma marketers to know: Thursday, January 12, 2017

By

Trump says pharma is "getting away with murder"; Senate majority votes to repeal ACA; IBM Watson Health and FDA to study blockchain technology

Infographic: Can pharma give doctors what they want?

Infographic: Can pharma give doctors what they want?

Physicians do not like EHRs. That much is clear. But the vast majority have to use electronic record systems on a daily basis. What can pharma do to better give doctors what they want?

Day 1 at JP Morgan: Pricing is top of mind for pharma CEOs

Day 1 at JP Morgan: Pricing is top of mind for pharma CEOs

By

The questions being asked about how drugs are priced are weighing heavily on pharma leaders, and they know the issue is not going away.

Five things for pharma marketers to know: Wednesday, January 4, 2017

Five things for pharma marketers to know: Wednesday, January 4, 2017

By

Sanofi, Regeneron denied bid to overturn Amgen win in patent case; Abbott to close St. Jude deal; Gilead hires SVP of hematology and oncology

Why healthbots may eat search ads and mobile apps

Why healthbots may eat search ads and mobile apps

By

The internet strongly agrees there's an artificial intelligence revolution going on, and it's come to pharma marketing.

MM&M's new logo reflects the evolving industry

MM&M's new logo reflects the evolving industry

By

This month we will debut a restyled MM&M logo on our website, in a mobile-friendly, redesigned email newsletter, and on the cover of our magazine.

Drugmakers: Take a Note From P&G, and Generate Some Goodwill

Drugmakers: Take a Note From P&G, and Generate Some Goodwill

We, as an industry, frighten rather than inform, cover our butts rather than support, and confuse rather than encourage.

MM&M launches search for 2017 Healthcare Transformers

MM&M launches search for 2017 Healthcare Transformers

By

It is also seeking industry input for a new category of honoree, the Top 10 Innovation Catalysts.

Five things for pharma marketers to know: Friday, December 9, 2016

Five things for pharma marketers to know: Friday, December 9, 2016

By

BMS to pay $19.5 million to settle marketing violations for Abilify; AstraZeneca to cut 700 U.S. jobs; Trump reportedly considering Jim O'Neill to lead FDA

OPINION

Newsletters